CAV1 and lung cancer: Although the decrease of Mcl-1 and Bcl-2 was notified after treatment with avicequinone B at 1–4 μM, the significantly reduction of caveolin-1 and induction of anoikis were only observed in human lung cancer cells incubated with avicequinone B at 4 μM.